Trials 24 · a red edge is where a trial was stopped
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 26 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Berzosertib | “Participants meeting inclusion and exclusion criteria will receive lurbinectedin (on day 1) and berzosertib (on day 1 and 2) administered every 21 days (1 cycle), either in the...” NCT04802174 ↗19“Berzosertib (M6620) is a highly potent (IC50 = 19 nM) and selective, first-in-class ataxia telangiectasia-mutated and Rad3-related protein kinase (ATR) inhibitor.” PMID 38129525 ↗ Dec 2023 “Berzosertib (formerly M6620, VX-970) is a highly potent and selective, first-in-class inhibitor of ataxia telangiectasia and Rad3-related protein kinase (ATR).” PMID 34040175 ↗ May 2021 |
| Known as | BERZOSERTIB (VE-822) | ChEMBL registry synonym — accepted as the source's own label CHEMBL3989870 ↗ |
| Known as | M6620 | “M6620 (VX-970) is a potent ATR inhibitor, with half maximal inhibitory concentration (IC(50) of 20 nanomolar and antitumor activity across a broad range of cell lines in...” NCT02723864 ↗5“Berzosertib (M6620) is a highly potent (IC50 = 19 nM) and selective, first-in-class ataxia telangiectasia-mutated and Rad3-related protein kinase (ATR) inhibitor.” PMID 38129525 ↗ Dec 2023 “Berzosertib (formerly M6620, VX-970) is a highly potent and selective, first-in-class inhibitor of ataxia telangiectasia and Rad3-related protein kinase (ATR).” PMID 34040175 ↗ May 2021 “Berzosertib will be supplied as 20 mg/mL M6620 to be diluted with 5% dextrose in water solution before intravenous infusion.” NCT04826341 ↗ |
| Known as | VE 822 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3989870 ↗ |
| Known as | VE-822 (BERZOSERTIB) | ChEMBL registry synonym — accepted as the source's own label CHEMBL3989870 ↗ |
| Known as | VX-970 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02723864 ↗ |
| Action | Inhibit | “inhibitor of ataxia telangiectasia and Rad3-related protein kinase (ATR)” PMID 34040175 ↗ May 2021 |
| Modality | Small molecule | “Berzosertib is a small-molecule ataxia telangiectasia and Rad3-related protein inhibitor.” PMID 40437704 ↗ May 2025 |
| Route | Intravenous | “intravenous berzosertib” PMID 34040175 ↗ May 2021 |
| Target | ATR | “inhibitor of ataxia telangiectasia and Rad3-related protein kinase (ATR)” PMID 34040175 ↗ May 2021 |